| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Silver NanoParticles (AgNPs) Summary: 1.Smaller sizes are generally more bioactive due to increased surface area and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect. 2.Two relevant forms: particulate silver (AgNPs) and ionic silver (Ag⁺). There is debate regarding oral use, as Ag⁺ can precipitate as AgCl in gastric acid, reducing bioavailability; AgNPs may partially avoid this via particulate uptake and intracellular Ag⁺ release. Gastric pH may influence this equilibrium. 3. Dose example 80kg person: 1.12-2mg/day, which can be calculated based on ppm and volume taken (see below) target < 10ppm and 120mL per day (30ppm and 1L per day caused argyria 30mg/day ) (Case Report: 9‐15 ppm@120mL, i.e. 1.1mg/L to 1.8mg/L per day) Likely 10ppm --> 10mg/L, hence if take 100mL, then 1mg/day? (for Cancer) The current Rfd for oral silver exposure is 5 ug/kg/d with a critical dose estimated at 14 ug/kg/d for the average person. Seems like the Cancer target range is 14ug/kg/day to 25ug/kg/day. 80Kg example: 1.12mg to 2mg “1.4µg/kg body weight. If I would have 70kg, I would want to use 100µg/day. However, for fighting active disease, I would tend to explore higher daily dose, as I think this may be too low.” These values reflect experimental or anecdotal contexts and are not established safe or therapeutic doses. 4. Antioxidants such as NAC can counteract AgNP cytotoxicity by restoring glutathione pools and suppressing ROS-mediated mitochondrial damage. 5. In vitro studies commonly show ROS elevation in both cancer and normal cells; however, in vivo, superior antioxidant, NRF2, and repair capacity in normal tissues may confer selectivity. 6. Pathways/mechanisms of action/: -” intracellular ROS was increased...reduction in levels of glutathione (GSH)” - Normal-cell selectivity is partly mediated by NRF2-dependent antioxidant and detoxification responses. - AgNPs impair mitochondrial electron transport, increasing electron leak and amplifying ROS upstream of ΔΨm collapse. -AgNPs inhibit VEGF-driven endothelial signaling and permeability (anti-angiogenic effect) -”upregulation of proapoptotic genes (p53, p21, Bax, and caspases) and downregulation of antiapoptotic genes (Bcl-2)” -” upregulation of AMPK and downregulation of mTOR, MMP-9, BCL-2, and α-SMA” -”p53 is a key player...proapoptotic genes p53 and Bax were significantly increased... noticeable reduction in Bcl-2 transcript levels” -” p53 participates directly in the intrinsic apoptosis pathway by regulating the mitochondrial outer membrane permeabilization” - “Proapoptotic markers (BAX/BCL-XL, cleaved poly(ADP-ribose) polymerase, p53, p21, and caspases 3, 8 and 9) increased.” -”The antiapoptotic markers, AKT and NF-kB, decreased in AgNP-treated cells.” Chronic accumulation and long-term systemic effects remain insufficiently characterized. Silver NanoParticles and Magnetic Fields Summary: 1. “exposure to PMF increased the ability of AgNPs uptake” 2. 6x improvement from AgNPs alone could glucose capping of SilverNPs work as trojan horse? Sodium selenite might protect against toxicity of AgNPs in normal cells. -uncoated AgNPs can degrade the gut microbiome. PVP, citrate, green-synthesized, chitosan coating, may reduce the effect. Similar oxidative considerations may apply to selenium compounds, though mechanisms differ. co-ingestion with food (higher pH) favors reduction and lower Ag+ levels. -action mechanisms of AgNPs: the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure. AgNP anticancer effects come from three overlapping mechanisms: -Nanoparticle–cell interaction (uptake, membrane effects) -Intracellular ROS generation -Controlled Ag⁺ release inside cancer cells Comparison adding Citrate Capping | Property | Uncapped AgNPs | Citrate-capped AgNPs | | --------------------- | -------------- | -------------------- | | Stability | Poor | Excellent | | Free Ag⁺ | High | Low | | Normal cell toxicity | Higher | Lower | | Cancer selectivity | Lower | **Higher** | | Mechanism specificity | Crude | **Targeted** | | Storage behavior | Degrades | Stable |
|
| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 4574- | AgNPs, | Advances in nano silver-based biomaterials and their biomedical applications |
| - | Review, | NA, | NA |
| 4564- | AgNPs, | GoldNP, | Cu, | Chemo, | PDT | Cytotoxicity and targeted drug delivery of green synthesized metallic nanoparticles against oral Cancer: A review |
| - | Review, | Var, | NA |
| 4561- | AgNPs, | VitC, | Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | HEK293 |
| 4554- | AgNPs, | Involvement of telomerase activity inhibition and telomere dysfunction in silver nanoparticles anticancer effects |
| - | in-vitro, | Cerv, | HeLa |
| 4553- | AgNPs, | Cytotoxicity induced by engineered silver nanocrystallites is dependent on surface coatings and cell types |
| - | in-vitro, | Nor, | RAW264.7 |
| 4552- | AgNPs, | ART/DHA, | Green synthesis of silver nanoparticles using Artemisia turcomanica leaf extract and the study of anti-cancer effect and apoptosis induction on gastric cancer cell line (AGS) |
| - | in-vitro, | GC, | AGS |
| 5142- | AgNPs, | Biosynthesized Protein-Capped Silver Nanoparticles Induce ROS-Dependent Proapoptotic Signals and Prosurvival Autophagy in Cancer Cells |
| - | in-vitro, | CRC, | HUH7 |
| 5977- | AgNPs, | CDT, | Silver Nitroprusside as an Efficient Chemodynamic Therapeutic Agent and a Peroxynitrite nanogenerator for Targeted Cancer Therapy |
| - | in-vivo, | Ovarian, | A2780S | - | NA, | Ovarian, | SKOV3 |
| 5976- | AgNPs, | Review on Harnessing Silver Nanoparticles for Therapeutic Innovations: A Comprehensive Review on Medical Applications, Safety, and Future Directions |
| - | Review, | Vit, | NA |
| 5975- | AgNPs, | PDT, | CDT, | RF, | Recent Advances in the Application of Silver Nanoparticles for Enhancing Phototherapy Outcomes |
| - | Review, | Var, | NA | - | Review, | BPH, | NA |
| 5237- | AgNPs, | Nrf2 Activation Mitigates Silver Nanoparticle-Induced Ferroptosis in Hepatocytes |
| - | in-vitro, | Liver, | HepG2 |
| 5236- | AgNPs, | Adaptive regulations of Nrf2 alleviates silver nanoparticles-induced oxidative stress-related liver cells injury |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| 5147- | AgNPs, | Size dependent anti-invasiveness of silver nanoparticles in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 5144- | AgNPs, | Differential effects of silver nanoparticles on DNA damage and DNA repair gene expression in Ogg1-deficient and wild type mice |
| - | in-vivo, | Nor, | NA |
| 4398- | AgNPs, | Induction of apoptosis in cancer cells at low silver nanoparticle concentrations using chitosan nanocarrier |
| - | in-vitro, | Colon, | HT29 |
| 4600- | AgNPs, | Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model |
| - | in-vivo, | Nor, | NA |
| 4424- | AgNPs, | Understanding the prospective of nano-formulations towards the treatment of psoriasis |
| - | in-vivo, | PSA, | NA |
| 4423- | AgNPs, | Pongamia pinnata seed extract-mediated green synthesis of silver nanoparticle loaded nanogel for estimation of their antipsoriatic properties |
| - | in-vivo, | PSA, | NA |
| 4421- | AgNPs, | Effect of Biologically Synthesized Silver Nanoparticles on Human Cancer Cells |
| - | in-vitro, | Cerv, | NA |
| 4415- | AgNPs, | SDT, | CUR, | Examining the Impact of Sonodynamic Therapy With Ultrasound Wave in the Presence of Curcumin-Coated Silver Nanoparticles on the Apoptosis of MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 4413- | AgNPs, | Anzaroot, | Green synthesis of silver nanoparticles from plant Astragalus fasciculifolius Bioss and evaluating cytotoxic effects on MCF7 human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4412- | AgNPs, | Biosynthesis and characterization of silver nanoparticles from Asplenium dalhousiae and their potential biological properties |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Melanoma, | A2780S |
| 4405- | AgNPs, | Silver nanoparticles defeat p53-positive and p53-negative osteosarcoma cells by triggering mitochondrial stress and apoptosis |
| - | in-vitro, | OS, | NA |
| 4404- | AgNPs, | Rad, | Main Approaches to Enhance Radiosensitization in Cancer Cells by Nanoparticles: A Systematic Review |
| - | Review, | Var, | NA |
| 4403- | AgNPs, | Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | GL26 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | RKO |
| 4400- | AgNPs, | Rad, | Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | BC, | MDA-MB-231 |
| 4399- | AgNPs, | Chit, | Silver nanoparticles impregnated alginate-chitosan-blended nanocarrier induces apoptosis in human glioblastoma cells |
| - | in-vitro, | GBM, | U87MG |
| 4551- | AgNPs, | Fenb, | Ångstrom-Scale Silver Particles as a Promising Agent for Low-Toxicity Broad-Spectrum Potent Anticancer Therapy |
| - | in-vivo, | Lung, | NA |
| 4545- | AgNPs, | VitC, | Citrate, | Ascorbic Acid-assisted Green Synthesis of Silver Nanoparticles: pH and Stability Study |
| - | Study, | NA, | NA |
| 4544- | AgNPs, | VitC, | Current Research on Silver Nanoparticles: Synthesis, Characterization, and Applications |
| - | Review, | Nor, | NA |
| 4447- | AgNPs, | Anti-inflammatory action of silver nanoparticles in vivo: systematic review and meta-analysis |
| - | Review, | Nor, | NA |
| 4547- | AgNPs, | GoldNP, | VitC, | Exploration of Biocompatible Ascorbic Acid Reduced and Stabilized Gold Nanoparticles, as Sensitive and Selective Detection Nanoplatform for Silver Ion in Solution |
| - | Study, | NA, | NA |
| 4549- | AgNPs, | Silver nanoparticles: Synthesis, medical applications and biosafety |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA |
| 1903- | AgNPs, | Novel Silver Complexes Based on Phosphanes and Ester Derivatives of Bis(pyrazol-1-yl)acetate Ligands Targeting TrxR: New Promising Chemotherapeutic Tools Relevant to SCLC Managemen |
| - | in-vitro, | Lung, | U1285 |
| 1906- | AgNPs, | GoldNP, | Cu, | Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors |
| - | Review, | Var, | NA |
| 1907- | AgNPs, | GoldNP, | Cu, | In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Colon, | HCT15 | - | in-vitro, | Cerv, | HeLa |
| 2205- | AgNPs, | Potential protective efficacy of biogenic silver nanoparticles synthesised from earthworm extract in a septic mice model |
| - | in-vivo, | Nor, | NA |
| 2207- | AgNPs, | TQ, | Protective effects of Nigella sativa L. seeds aqueous extract-based silver nanoparticles on sepsis-induced damages in rats |
| - | in-vivo, | Nor, | NA |
| 2286- | AgNPs, | Short-term changes in intracellular ROS localisation after the silver nanoparticles exposure depending on particle size |
| - | in-vitro, | Nor, | 3T3 |
| 2287- | AgNPs, | Silver nanoparticles induce endothelial cytotoxicity through ROS-mediated mitochondria-lysosome damage and autophagy perturbation: The protective role of N-acetylcysteine |
| - | in-vitro, | Nor, | HUVECs |
| 2538- | AgNPs, | SDT, | Z, | Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment |
| - | Study, | Var, | NA | - | vitro+vivo, | NA, | NA |
| 2835- | AgNPs, | Gluc, | Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake |
| - | in-vitro, | Liver, | HepG2 |
| 2836- | AgNPs, | Gluc, | Glucose capped silver nanoparticles induce cell cycle arrest in HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 2837- | AgNPs, | Trojan-Horse Mechanism in the Cellular Uptake of Silver Nanoparticles Verified by Direct Intra- and Extracellular Silver Speciation Analysis |
| - | in-vitro, | NA, | NA |
| 4358- | AgNPs, | HPT, | Rad, | Silver nanocrystals mediated combination therapy of radiation with magnetic hyperthermia on glioma cells |
| - | in-vitro, | GBM, | U251 |
| 4378- | AgNPs, | Exploring silver nanoparticles for cancer therapy and diagnosis |
| - | Review, | Var, | NA |
| 4379- | AgNPs, | Exposure to silver nanoparticles induces size- and dose-dependent oxidative stress and cytotoxicity in human colon carcinoma cells |
| - | in-vitro, | CRC, | LoVo |
| 4380- | AgNPs, | Silver nanoparticles induce toxicity in A549 cells via ROS-dependent and ROS-independent pathways |
| - | in-vitro, | Lung, | A549 |
| 4381- | AgNPs, | Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells |
| - | in-vitro, | Liver, | HepG2 |
| 4383- | AgNPs, | Exploring the Potentials of Silver Nanoparticles in Overcoming Cisplatin Resistance in Lung Adenocarcinoma: Insights from Proteomic and Xenograft Mice Studies |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:153 Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid